Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 305

Sort by

Sort Order Select

Journal Articles

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Alissa Visram, Dirk Larson, Aaron D Norman, Angela Dispenzieri, David L Murray, Robert A Kyle, S. Vincent Rajkumar, Susan L. Slager, Shaji K Kumar, Celine M. Vachon

Blood blood.2024025415.

https://doi.org/10.1182/blood.2024025415

Published: 2024

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

Optimal Sequencing Determination in Relapsed Multiple Myeloma

Salyka M. Sengsayadeth, Bridget Fitzgerald, Bharat Nandakumar, Bicky Thapa, Timothy Martin Schmidt, Rebecca Silbermann, Heidi Chen, Saurabh Chhabra, Natalie Callander, Shaji K Kumar, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 10033–10035.

https://doi.org/10.1182/blood-2022-169589

Published: 2022

Journal Articles

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Shaji K Kumar, Alfred L. Garfall, Suzanne Trudel, Enrique M. Ocio, Emma Scott, Lin Huang, Xuewen Ma, Yunsi Olyslager, Payal Thakkar, Lixia Pei, Christoph Heuck, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 7292–7293.

https://doi.org/10.1182/blood-2022-163260

Published: 2022

Journal Articles

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Blood (2022) 140 (Supplement 1): 10017–10019.

https://doi.org/10.1182/blood-2022-167181

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Blood (2022) 140 (Supplement 1): 10150–10153.

https://doi.org/10.1182/blood-2022-163335

Published: 2022

Journal Articles

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Blood (2022) 140 (Supplement 1): 8092–8093.

https://doi.org/10.1182/blood-2022-164617

Published: 2022

Journal Articles

Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7141–7143.

https://doi.org/10.1182/blood-2022-163746

Published: 2022

Journal Articles

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Reyka G. Jayasinghe, George Mulligan, April Cook, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn J. Cho, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 7090–7091.

https://doi.org/10.1182/blood-2022-167462

Published: 2022

Journal Articles

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

David Sharon, Fengjiao Dunbar, Paul Jung, Xifeng Wang, Xiaotong Li, Christine Mantis, Orlando F. Bueno, Cyrille Touzeau, Philippe Moreau, Simon J Harrison, Luciano J. Costa, Jonathan L. Kaufman, Nizar J. Bahlis, Shaji K Kumar, Jeremy A. Ross, P.K. Epling-Burnette

Blood (2022) 140 (Supplement 1): 4242–4244.

https://doi.org/10.1182/blood-2022-160195

Published: 2022

Journal Articles

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Blood (2022) 140 (Supplement 1): 10942–10944.

https://doi.org/10.1182/blood-2022-164785

Published: 2022

Journal Articles

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Blood (2022) 140 (Supplement 1): 10068–10070.

https://doi.org/10.1182/blood-2022-162754

Published: 2022

Journal Articles

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Eli Muchtar, Surendra Dasari, Martha Grogan, Morie A. Gertz, Martha Q. Lacy, Francis K. Buadi, David Dingli, Taxiarchis Kourelis, Itzhak Z. Attia, Francisco Lopez-Jimenez, Dennis Murphree, Paul A. Friedman, Shaji K Kumar, Angela Dispenzieri

Blood (2022) 140 (Supplement 1): 7230–7232.

https://doi.org/10.1182/blood-2022-168119

Published: 2022

Journal Articles

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

Moritz Binder, Amelia Mazzone, Jenna A. Fernandez, Wazim Mohammed Ismail, S. Vincent Rajkumar, Alexandre Gaspar Maia, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 9978–9979.

https://doi.org/10.1182/blood-2022-162679

Published: 2022

Journal Articles

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Alexander J Ryu, Shaji K Kumar, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Thomas C Kingsley

Blood (2022) 140 (Supplement 1): 7842–7843.

https://doi.org/10.1182/blood-2022-169376

Published: 2022

Journal Articles

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Salsabil Ahmed, Suman Mazumder, Lisa Wiesen, Neeraj Sharma, Ujjal Kumar Mukherjee, Shaji K Kumar, Linda B. Baughn, Brian G. Van Ness, Amit Kumar Mitra

Blood (2022) 140 (Supplement 1): 4249–4250.

https://doi.org/10.1182/blood-2022-164501

Published: 2022

Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Blood (2022) 140 (Supplement 1): 1830–1832.

https://doi.org/10.1182/blood-2022-168930

Published: 2022

Journal Articles

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 2347–2348.

https://doi.org/10.1182/blood-2022-167430

Published: 2022

Journal Articles

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Paula Rodríguez Otero, Nisha S. Joseph, Shaji K Kumar, Hans C. Lee, Xavier Leleu, Salomon Manier, Meletios A. Dimopoulos, María Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M. Sarkaria

Blood (2022) 140 (Supplement 1): 4444–4446.

https://doi.org/10.1182/blood-2022-157713

Published: 2022

NARROW

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Optimal Sequencing Determination in Relapsed Multiple Myeloma

MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event

Artificial Intelligence-Enhanced Models to Predict Light Chain Amyloidosis from Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only